Herborium Group Names Dr. Harold Mermelshein MD to Its Scientific Advisory Board
June 15 2010 - 11:07AM
Marketwired
Herborium Group, Inc. (PINKSHEETS: HBRM), a Botanical Therapeutics™
company, today announced the appointment of Dr. Harold Mermelshein,
MD, a renowned New York dermatologist, to Herborium's Scientific
Advisory Board.
"I'm pleased that such a prestigious dermatologist as Dr.
Mermelshein has agreed to serve on our Scientific Advisory Board,"
commented Dr. Agnes P. Olszewski, Herborium Group's president and
chief executive officer. "Dr. Mermelshein's career spans more than
30 years, during which time he has distinguished himself as a
dedicated, learned advocate in dermatological academia, research,
and clinical practice as well as pioneer in using complementary,
scientifically based, alternative treatment modalities in clinical
practice."
Dr. Mermelshein is Board Certified by, and a standing member of,
the American Academy of Dermatology. A magna cum laude alumnus of
New York Medical College. Dr. Mermelshein has served as Chief of
Residency for New York University Medical Center's Skin and Cancer
Unit and, since 1988, as the Associate Clinical Professor of the
Center Dermatology Department.
Dr. Olszewski continued, "With Herborium's flagship product,
AcnEase®, now available through an increasing number of
distribution channels in the US and abroad, we are focusing on
strengthening its consumer and professional brand recognition. Dr.
Mermelshein will play a key role in meeting and maintaining only
the highest standards expected by medical professionals and
consumers, further strengthening Herborium's differential brand
advantage. To that end, he will advise management regarding the
Company's proactive clinical validation and regulatory strategy
speared the U.S. Food and Drug Administration's (FDA) guidance for
the botanical drug product industry (FDA Guidance 2004)."
"With Herborium's business model based on clinical testing
confirmation of our products efficacy, having Dr. Mermelshein among
our team of medical experts will also facilitate further
advancement of our clinical testing, and therefore strengthen a
differential advantage and marketability of our products growing,"
concluded Dr. Olszewski.
About Herborium Group, Inc. Herborium
Group, Inc., a botanical therapeutics® company, focuses on
developing, licensing, and marketing proprietary, botanical based
medicinal products to consumers and healthcare professionals. The
Company business model focuses on emerging market opportunities
spearheaded by the growth of a new market sector located between
high-cost, high-risk, ethical pharmaceuticals and commoditized
classic nutraceuticals (supplements). The Company uses clinical
validation and a proactive regulatory strategy based on the FDA
Guidance for Industry: Botanical Drug Products (FDA Guidance 2004)
to establish and maintain a differential advantage. Herborium
harvests its therapeutic candidates from Traditional Chinese
Medicine and utilizes Western regulatory, clinical and marketing
strategies to successfully introduce the products to the Western
markets. The company secured a pipeline of botanical ingredients
based products in the areas of dermatological needs, Prostate
Health (BPH), Liver Diseases, Women's Health and selected sexual
disorders resulting from cardiovascular disease, use of
anti-depressants, surgical procedures, and other problems.
Herborium Group sells its products in the United States, the United
Kingdom, and continental Europe through a network of distributors,
specialty retailers, and e-commerce.
One of our most important responsibilities is to communicate
with shareholders in an open and direct manner. Comments are based
on current management expectations, and are considered
"forward-looking statements," generally preceded by words such as
"plans," "expects," "believes," "anticipates," or "intends." We
cannot promise future returns. Our statements reflect our best
judgment at the time they are issued, and we disclaim any
obligation to update or alter forward-looking statements as the
result of new information or future events. Adino Energy
Corporation urges investors to review the risks and uncertainties
contained within its filings with the Securities and Exchange
Commission.
Company Contact: Dr. Agnes P. Olszewski President &
CEO (201) 647-3757
Herborium (PK) (USOTC:HBRM)
Historical Stock Chart
From May 2024 to Jun 2024
Herborium (PK) (USOTC:HBRM)
Historical Stock Chart
From Jun 2023 to Jun 2024